# OnCo record gap-phase2-mdacc (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/gap-phase2-mdacc/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "gap-phase2-mdacc", "NCT02392637" ;
  schema:name "Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)"@en ;
  schema:alternateName "GAP phase 2"@en ;
  schema:description "The 60-patient study that made the chemotherapy triplet look promising in bile duct and gallbladder cancer: nearly half responded and median survival was 19 months, results that the larger S1815 trial later failed to confirm."@en ;
  schema:url <https://onco.cc/trials/gap-phase2-mdacc/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02392637>, <https://doi.org/10.1001/jamaoncol.2019.0270> ;
  onco:status "completed" ;
  onco:tag "lesson:single-arm-phase-2" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/nab-paclitaxel/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/mayo-clinic/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gap-phase2-mdacc-jama-oncol-2019/> .